Abbott Laboratories (ABT) is slated to report its second-quarter 2024 results on Jul 18, before the opening bell.The company posted adjusted earnings per share (EPS) of 98 cents in the last quarter, which topped the Zacks Consensus Estimate by 2.08%. In the trailing four quarters, its earnings exceeded the Zacks Consensus Estimate on all four occasions, the average beat being 2.39%.Q2 EstimatesThe Zacks Consensus Estimate for ABT’s second-quarter 2024 revenues is pegged at $10.35 billion. This suggests a 3. ...

Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?Before we discuss the reliability of brokerage recommendations and how to use them to your advantage, let's see what these Wall Street heavyweights think about Abbott (ABT) .Abbott currently has an average brokerage recommendation (AB ...

In my view, it’s important for every individual to invest in equities. By just holding cash in a back account, there is bound to be loss of purchasing power when adjusted for inflation. To maintain or increase purchasing power, investors need exposure to risky asset classes.However, not all investors have the appetite for high-risk that’s associated with growth or penny stocks. The remedy is to invest in low-beta stocks that deliver steady returns and protect the portfolio from extreme volatility. The focus ...

公司表现 - 公司最新交易日收盘价为$101.64，较前一交易日下跌0.47%，表现落后于S&P 500指数的0.07%涨幅，同时道琼斯指数下跌0.13%，纳斯达克指数上涨0.14% [1] - 公司股价在过去一个月内下跌了5%，未能跟上医疗行业1.99%的跌幅和S&P 500指数4.34%的涨幅 [1] - 公司预计将于2024年7月18日发布财报，预计每股收益(EPS)为$1.10，同比增长1.85%，营收预计为$10.35 billion，同比增长3.78% [1] - 全年预计每股收益为$4.62，营收为$41.66 billion，分别同比增长4.05%和3.86% [2] 分析师估计与估值 - 公司目前的Zacks Rank为3 (Hold)，过去30天内Zacks Consensus EPS估计保持不变 [3] - 公司当前的Forward P/E比率为22.11，高于其行业平均的21.87 [3] - 公司的PEG比率为2.46，高于医疗产品行业平均的2.24 [3] 行业分析 - 医疗产品行业属于医疗行业，目前Zacks Industry Rank为166，位于所有250+行业的底部35% [4] - Zacks Industry Rank通过衡量行业内个股的平均Zacks Rank来评估行业实力，研究表明，排名前50%的行业表现优于后50%的行业，比例为2:1 [4]

undefined/iStock via Getty Images 2024 Review A positive trajectory resumed for the ProShares S&P 500 Dividend Aristocrats ETF (NOBL) during the month of May. The ETF posted a modest gain of 1.45% during the month. Albeit some of this optimism has faded in June with the ETF sitting in the red near the end of the month. Year-to-date, through June 26th NOBL is up 2.44%. Several dividend aristocrats are running at a much faster pace than NOBL in 2024. Let's take a look at which individual aristocrats are drivi ...

Fundamentally, few sectors exist outside of the broad healthcare umbrella that offer what I would term permanent relevance. In this case, the concept of caring for other people is likely an eternal one. So, it makes sense to consider medical technology or MedTech stocks to buy.As you know, the innovation ecosystem constantly moves in one direction: forward. It seems like every day, someone is talking about artificial intelligence or automated robotics or some invention in the connectivity arena. Enterprises ...

ssuaphoto Foreword This article is based on Fortune magazine's 2024 survey of 500 Largest U.S. Corporations (F500-IL). The Fortune 500, in its 70th year, ranks the biggest U.S. companies by revenue. In total, Fortune 500 companies represent two-thirds of the U.S. GDP with $18.8 trillion in revenues, $1.7 trillion in profits, and $43 trillion in market value (as of March 28, 2024), and they employ 31 million people worldwide. This article covers the top profit generating companies in 66 industries. Any colle ...

ABBOTT PARK, Ill., June 27, 2024 /PRNewswire/ -- Abbott (NYSE: ABT) will announce its second-quarter 2024 financial results on Thursday, July 18, before the market opens. The announcement will be followed by a live webcast of the earnings conference call at 8 a.m. Central time (9 a.m. Eastern) and will be accessible through Abbott's Investor Relations website at www.abbottinvestor.com. An archived edition of the call will be available later that day.About Abbott:Abbott is a global healthcare leader that hel ...

Abbott’s (ABT) diversified business portfolio is well-positioned to drive continued momentum in 2024. However, a challenging macroeconomic environment continues to dent Abbott’s business globally. The stock carries a Zacks Rank #3 (Hold) currently.Abbott continues to expand its Diagnostics business foothold (consisting of 22.2% of the total revenues in the first quarter of 2024). Over the past few quarters, the company has witnessed increased demand for routine diagnostics, particularly in the United States ...

Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?Before we discuss the reliability of brokerage recommendations and how to use them to your advantage, let's see what these Wall Street heavyweights think about Abbott (ABT) .Abbott currently has an average brokerage recommendation (AB ...